The first and only CAR T-cell therapy for adults with R/R MANTLE CELL LYMPHOMA, APPROVED
WITH BREAKTHROUGH THERAPY DESIGNATION, NOW HAS ~3 years median study follow-up1-3*


TECARTUS® treatment process
Relapsed/Refractory mantle cell lymphoma graph

Primary analysis

87% ORR (n=52/60)

  • Median study follow-up: 12.3 months1,5

62% CR (n=37/60)1

24-month analysis*

36.5 months mDOR
(n=52; 95% Cl: 14.4, 47.1) at a median study
follow-up of 35.6 months3,4,6

BTKi=Bruton’s tyrosine kinase inhibitor; CAR=chimeric antigen receptor; CD=cluster of differentiation; CI=confidence interval; CR=complete response; DOR=duration of response; mDOR=median duration of response; ORR=objective response rate; PFS=progression-free survival; R/R=relapsed or refractory; USPI=US Prescribing Information.

References: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021. 2. U.S. FDA approves Kite’s TECARTUS®, the first and only CAR T treatment for relapsed or refractory mantle cell lymphoma. News release. Kite, a Gilead Company; July 24, 2020. Accessed February 13, 2023.’s-Tecartus™-the-First-and-Only-CAR-T-Treatment-for-Relapsed-or-Refractory-Mantle-Cell-Lymphoma 3. Data on file [1]. Kite Pharma, Inc; 2022. 4. Data on file [2]. Kite Pharma, Inc; 2022. 5. Data on file. Kite Pharma, Inc; 2020. 6. Data on file [3]. Kite Pharma, Inc; 2022. 7. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle cell lymphoma. N Engl J Med. 2020;382(14):1331-1342.